Cipher Pharmaceuticals Inc
TSX:CPH

Watchlist Manager
Cipher Pharmaceuticals Inc Logo
Cipher Pharmaceuticals Inc
TSX:CPH
Watchlist
Price: 14.74 CAD 0.55%
Market Cap: 377.2m CAD
Have any thoughts about
Cipher Pharmaceuticals Inc?
Write Note

Cipher Pharmaceuticals Inc
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Cipher Pharmaceuticals Inc
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Cipher Pharmaceuticals Inc
TSX:CPH
Income from Continuing Operations
$15.9m
CAGR 3-Years
48%
CAGR 5-Years
N/A
CAGR 10-Years
-7%
Bausch Health Companies Inc
TSX:BHC
Income from Continuing Operations
-$217m
CAGR 3-Years
43%
CAGR 5-Years
19%
CAGR 10-Years
N/A
Sundial Growers Inc
NASDAQ:SNDL
Income from Continuing Operations
-CA$172m
CAGR 3-Years
6%
CAGR 5-Years
-25%
CAGR 10-Years
N/A
Cronos Group Inc
TSX:CRON
Income from Continuing Operations
-$49.1m
CAGR 3-Years
49%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
Income from Continuing Operations
-$97.8m
CAGR 3-Years
-3%
CAGR 5-Years
-144%
CAGR 10-Years
-99%
C
Curaleaf Holdings Inc
CNSX:CURA
Income from Continuing Operations
-$563m
CAGR 3-Years
-119%
CAGR 5-Years
-343%
CAGR 10-Years
N/A
No Stocks Found

Cipher Pharmaceuticals Inc
Glance View

Market Cap
377.2m CAD
Industry
Pharmaceuticals

Cipher Pharmaceuticals, Inc. engages as a specialty pharmaceutical company, which have diversified portfolio of commercial and early to late-stage products. The company is headquartered in Oakville, Ontario. The company went IPO on 2004-02-25. The firm acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products directly in Canada and indirectly through partners in the United States, Canada and South America. Its Dermatology products include Actikerall, Epuris, Ozanex, and Vaniqa. Its Hospital Acute Care products are Aggrastat and Brinavess. The Company’s Out-Licensed Products include Absorica, ConZip, Durela, and Lipofen. The company is focused on three strategy that includes acquisitions, in-licensing, and selective investments in drug development to assemble a portfolio of prescription products that serve unmet medical needs. The firm's subsidiaries include Cipher US Holdings Inc., Cipher US Holdco LLC and Cipher Pharmaceuticals US LLC.

CPH Intrinsic Value
11.79 CAD
Overvaluation 20%
Intrinsic Value
Price

See Also

What is Cipher Pharmaceuticals Inc's Income from Continuing Operations?
Income from Continuing Operations
15.9m USD

Based on the financial report for Sep 30, 2024, Cipher Pharmaceuticals Inc's Income from Continuing Operations amounts to 15.9m USD.

What is Cipher Pharmaceuticals Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
-7%

Over the last year, the Income from Continuing Operations growth was -51%. The average annual Income from Continuing Operations growth rates for Cipher Pharmaceuticals Inc have been 48% over the past three years , and -7% over the past ten years .

Back to Top